Characterization of CD22 expression in acute lymphoblastic leukemia - Wikidata - wikimedia - TriplyDB

Characterization of CD22 expression in acute lymphoblastic leukemia

Characterization of CD22 expression in acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q35514128

about

Recent advances and novel treatment paradigms in acute lymphocytic leukemia Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia.CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.Acute lymphoblastic leukemia: a comprehensive review and 2017 update Advances in adult acute lymphoblastic leukemia therapy.Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia.Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.

P2860

Q28078076-5832F8CB-59AA-4A68-BBB6-44A1064666C6 Q33761496-CE2687FB-504F-457B-8BA3-2654CFF471D3 Q36917916-58FFDAD7-5DD0-4C57-B40F-732CDE7E4E2B Q38665500-90F3107B-8BDD-477B-9134-D5813647CE9D Q38813257-C67FA768-8AA1-48E9-A652-D0199888A993 Q39401736-094EC573-057B-4524-824F-D39D910C6DFF Q39406969-1C5FB25C-6F06-4682-A013-92482E9A7DA1 Q39459190-499BFAA8-B30E-4B45-9CDE-BF64C88D1973 Q40705613-7DD4483E-FBA1-4597-8D3A-954CAF635EAD Q41637417-B59D6D5E-C043-4B4F-81F6-E48738A55F73 Q45871879-C4437BF5-8215-4C7B-AA1A-85D9DB143C70 Q46364067-0BE1899A-CE9A-4306-8A76-85E18AE6D8A9 Q46385489-8FE54C94-E188-403A-88AC-90BAF5A43AB8 Q47820469-2E75C7C7-F211-4704-9020-0EBD2B4B0E70 Q48272279-B1C95A59-F151-457E-B2FB-51624AA3DEA0 Q48800056-E5F65E5D-7F6D-47F4-ADC3-49B96701F5B9 Q50054479-46FE1DDF-26F0-4688-95E6-F498A356D742 Q50063870-D34D2905-0741-4A7B-B598-F37B3090B449 Q51031788-81BAFB35-E7C3-4BC7-9EEF-515881D36795

P2860

Characterization of CD22 expression in acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q35514128

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Characterization of CD22 expression in acute lymphoblastic leukemia

@ast

Characterization of CD22 expression in acute lymphoblastic leukemia

@en

type

label

Characterization of CD22 expression in acute lymphoblastic leukemia

@ast

Characterization of CD22 expression in acute lymphoblastic leukemia

@en

prefLabel

Characterization of CD22 expression in acute lymphoblastic leukemia

@ast

Characterization of CD22 expression in acute lymphoblastic leukemia

@en

P1433

Q35514128-2AC58E92-855D-46CC-A44A-4D588F35DADE

P1476

Q35514128-2CE43C86-7FC7-400A-9AB0-4265CEE290D7

P2093

Q35514128-23504512-EB76-46EC-960A-CDBEF6526447

Q35514128-49902AD3-3E3D-4B41-88CD-0220A6489C92

Q35514128-60238E45-C437-4ACD-9F39-7C6F65D6784A

Q35514128-6B4CAB83-DDDA-4F07-90E8-DC0847FF3266

Q35514128-7ABDADF4-7467-4F33-89ED-79F348375E63

Q35514128-ACF4C2F5-F070-4D1E-99DB-105695789751

Q35514128-BA308248-9B99-46B6-9FC1-5A9AFBCA85A6

Q35514128-CCF88BD9-17F7-4B13-900D-036D6593C18C

P2860

Q35514128-02C52081-1619-4E19-85FD-E5E1FBACD015

Q35514128-233ED386-78F5-45CD-809C-D6CC7F3BC2E6

Q35514128-36DE59D0-689E-4D91-90D2-B3A689C8D4FD

Q35514128-3C09B03A-D392-4097-BEC5-B598CE7D3469

Q35514128-54A597D9-D20A-4D08-B721-431054250DC2

Q35514128-707D0D74-0EE1-4563-95BF-FE17A3A768CE

Q35514128-7C15C6A6-B198-4E84-A2AD-87F4551E6DA7

Q35514128-7C8B57F7-7F56-46A8-9627-CF887119ED4C

Q35514128-988042E6-DCAE-41D7-BBA4-C958594B8727

Q35514128-A8003CE2-2F93-44AC-8BFF-F6247A5CFF4D

P304

Q35514128-04EC40D2-1365-4C67-A559-2B63162FF018

P31

Q35514128-44BC7199-1679-42C1-B71C-6E539C2E445C

P356

Q35514128-9DB49E06-90A7-41B1-A2AF-4B4C167E03FC

P433

Q35514128-F9A0DF2F-9214-462E-8E7E-21AEDB01D493

P478

Q35514128-D006C50F-5A16-41EE-92E7-917137A3EE62

P577

Q35514128-7671BC1B-9306-4C47-A676-07C31643A3F2

P698

Q35514128-958A8DF7-395B-4BF1-9F1E-9E9523B57510

P921

Q35514128-7CC9E43F-FAA7-42BF-8F27-63FC02A66F0E

P932

Q35514128-43B19301-C912-4413-BA26-DEBB304B16A8

P356

P1433

Pediatric Blood & Cancer

P1476

Characterization of CD22 expression in acute lymphoblastic leukemia

@en

P2093

Alan S Wayne

http://www.w3.org/2001/XMLSchema#string

Cindy Delbrook

http://www.w3.org/2001/XMLSchema#string

Constance M Yuan

http://www.w3.org/2001/XMLSchema#string

Ira Pastan

http://www.w3.org/2001/XMLSchema#string

Kelly Richards

http://www.w3.org/2001/XMLSchema#string

Maryalice Stetler Stevenson

http://www.w3.org/2001/XMLSchema#string

Nirali N Shah

http://www.w3.org/2001/XMLSchema#string

Robert J Kreitman

http://www.w3.org/2001/XMLSchema#string

P2860

Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

Chronic health conditions in adult survivors of childhood cancer.

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.

P304

964-969

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.25410

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25728039

http://www.w3.org/2001/XMLSchema#string

P921

P932

4405453

http://www.w3.org/2001/XMLSchema#string